◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › G › GRFS

Grifols SA ADR (GRFS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · DATA UPDATED 2026-09-12

Grifols SA ADR (GRFS) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Barcelona, Spain with about 25,258 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, GRFS reported €7.2B in revenue and €386M in net income.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Interactive charts & full statements → Open the GRFS valuation workbench →

GRFS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	€7.4B	€7.2B	€7.2B	€6.6B	€6.1B	€4.9B	€5.3B	€5.1B	€4.5B	€4.3B	€4.0B	€3.9B	€3.4B	€2.7B	€2.6B	€1.8B	€991M	€913M	€814M	€703M	€649M
Gross Profit	€2.8B	€2.6B	€2.8B	€2.5B	€2.2B	€2.0B	€2.3B	€2.3B	€2.0B	€2.2B	€1.9B	€1.9B	€1.7B	€1.4B	€1.3B	€1.3B	€763M	€741M	€639M	€524M	€446M
Gross Margin %	37.2%	35.7%	38.8%	37.7%	36.5%	39.8%	42.2%	45.9%	45.7%	49.8%	47.2%	49.1%	50.6%	51.7%	50.7%	74.0%	77.0%	81.2%	78.4%	74.5%	68.7%
Operating Income (EBIT)	€1.2B	€1.2B	€1.2B	€782M	€782M	€595M	€996M	€1.1B	€994M	€1.0B	€939M	€970M	€858M	€736M	€660M	€279M	€210M	€227M	€203M	€146M	€100M
Operating Margin %	16.7%	16.4%	16.5%	11.9%	12.9%	12.1%	18.6%	22.2%	22.2%	23.2%	23.2%	24.7%	25.6%	26.9%	25.2%	15.5%	21.2%	24.8%	24.9%	20.8%	15.5%
Net Income	€452M	€386M	€157M	€42M	€185M	€189M	€619M	€625M	€597M	€663M	€545M	€532M	€470M	€346M	€257M	€50M	€116M	€148M	€122M	€88M	€45M
Net Margin %	6.1%	5.3%	2.2%	0.6%	3.0%	3.8%	11.6%	12.3%	13.3%	15.3%	13.5%	13.5%	14.0%	12.6%	9.8%	2.8%	11.7%	16.2%	14.9%	12.5%	7.0%
EBITDA	€1.7B	€1.6B	€1.5B	€1.2B	€1.2B	€944M	€1.4B	€1.4B	€1.3B	€1.2B	€1.1B	€1.1B	€1.0B	€849M	€803M	€360M	€243M	€258M	€222M	€165M	€101M
Earnings Per Share (EPS)	€0.66	€0.57	€0.23	€0.06	€0.27	€0.28	€0.90	€0.94	€0.87	€0.97	€0.80	€0.78	€0.69	€0.51	€0.37	€0.08	€0.26	€0.31	€0.25	€0.18	€0.11
Shares Outstanding (M)	681M	681M	680M	680M	680M	682M	686M	664M	685M	684M	684M	686M	685M	681M	685M	660M	442M	484M	487M	490M	430M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRFS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	€1.9B	€1.7B	€2.0B	€1.9B	€1.9B	€1.8B	€2.0B	€1.8B
Gross Profit	€704M	€630M	€680M	€752M	€744M	€705M	€766M	€727M
Gross Margin %	37.6%	36.5%	34.7%	40.3%	39.3%	39.5%	38.8%	40.5%
Operating Income (EBIT)	€329M	€253M	€272M	€383M	€349M	€269M	€372M	€317M
Operating Margin %	17.6%	14.6%	13.9%	20.5%	18.4%	15.1%	18.8%	17.7%
Net Income	€154M	€74M	€97M	€127M	€117M	€60M	€69M	€52M
Net Margin %	8.2%	4.3%	5.0%	6.8%	6.2%	3.3%	3.5%	2.9%
EBITDA	€535M	€361M	€396M	€457M	€347M	€405M	€337M	€468M
Earnings Per Share (EPS)	€0.23	€0.11	€0.14	€0.19	€0.17	€0.09	€0.10	€0.08
Shares Outstanding (M)	681M	681M	681M	681M	689M	680M	680M	680M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRFS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	€1.1B	€1.0B	€902M	€219M	(€11M)	€597M	€1.1B	€569M	€737M	€842M	€553M	€743M	€979M	€592M	€507M	€220M	€104M	€88M	€73M	€89M	€49M
Capital Expenditures (CapEx)	€376M	€255M	€371M	€310M	€376M	€315M	€363M	€412M	€308M	€323M	€293M	€567M	€287M	€173M	€166M	€160M	€103M	€119M	€0M	€0M	€0M
Free Cash Flow (FCF)	€719M	€751M	€531M	(€92M)	(€386M)	€282M	€748M	€157M	€430M	€519M	€261M	€176M	€692M	€419M	€341M	€60M	€1M	(€31M)	€73M	€89M	€49M
FCF Margin %	9.7%	10.4%	7.4%	-1.4%	-6.4%	5.7%	14.0%	3.1%	9.6%	12.0%	6.4%	4.5%	20.6%	15.3%	13.0%	3.4%	0.1%	-3.4%	9.0%	12.6%	7.6%
Dividends Paid	—	€123M	€1M	€0M	€1M	€259M	€113M	€239M	€279M	€218M	€216M	€222M	€156M	€69M	€281M	—	€27M	€81M	€35M	€13M	€7M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRFS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	€227M	€112M	€431M	€325M	€155M	€135M	€515M	€300M
Capital Expenditures (CapEx)	€119M	€53M	€134M	€70M	€60M	€49M	€100M	€84M
Free Cash Flow (FCF)	€108M	€59M	€297M	€255M	€95M	€86M	€414M	€215M
FCF Margin %	5.8%	3.4%	15.1%	13.7%	5.0%	4.8%	21.0%	12.0%
Dividends Paid	—	€25M	€26M	€102M	—	—	€1M	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRFS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	€20.1B	€19.8B	€21.4B	€21.0B	€21.2B	€19.2B	€15.3B	€17.4B	€12.5B	€10.9B	€10.1B	€9.6B	€8.4B	€5.8B	€5.6B	€5.8B	€1.9B	€1.7B	€1.2B	€940M	€914M
Cash & Cash Equivalents	€513M	€825M	€980M	€530M	€549M	€655M	€580M	€833M	€1.0B	€887M	€895M	€1.1B	€1.1B	€709M	€473M	€341M	€240M	€249M	€6M	€6M	€27M
Total Liabilities	€12.1B	€12.1B	€12.8B	€13.5B	€13.3B	€11.9B	€8.6B	€9.7B	€7.8B	€7.3B	€6.4B	€6.3B	€5.8B	€3.7B	€3.7B	€4.1B	€1.2B	€1.1B	€699M	€555M	€545M
Total Debt (Short + Long-Term)	€7.6B	€8.5B	€9.1B	€9.2B	€8.8B	€8.5B	€6.2B	€6.4B	€6.0B	€6.0B	€4.9B	€5.1B	€5.1B	€3.6B	€3.6B	€3.8B	€1.1B	€1.1B	€152M	€184M	€137M
Total Shareholders' Equity	€5.5B	€5.3B	€5.9B	€5.4B	€5.6B	€5.5B	€5.1B	€5.4B	€4.2B	€3.6B	€3.7B	€3.3B	€2.7B	€2.1B	€1.9B	€1.7B	€693M	€566M	€480M	€383M	€368M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GRFS viewer.

Other Companies in DRUG MANUFACTURERS - GENERAL

AZN · AstraZeneca PLC — $258 billion
NVO · Novo Nordisk A/S — $191 billion
SNY · Sanofi ADR — $102 billion
GSK · GlaxoSmithKline PLC ADR — $101 billion
OGN · Organon & Co — $4 billion
NVS · Novartis AG ADR — $267 billion

← GREN All “G” companies GRG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.